|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hao X: Cancer epidemiology and prevention
in China. Hua Xia Yi Yao. 4:335–339. 2009.(In Chinese).
|
|
4
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wein AJ, Kavoussi LR, Novick AC, Partin AW
and Peters CA: Campbell-Walsh Urology. 9th. Saunders Elsevier;
Philadelphia, PA: 2007, View Article : Google Scholar
|
|
6
|
Beck SD, Patel MI, Snyder ME, et al:
Effect of papillary and chromophobe cell type on disease-free
survival after nephrectomy for renal cell carcinoma. Ann Surg
Oncol. 11:71–77. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Zhou X, Zhou T, et al:
Ecto-5′-nucleotidase promotes invasion, migration and adhesion of
human breast cancer cells. J Cancer Res Clin Oncol. 134:365–372.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jin D, Fan J, Wang L, Thompson LF, Liu A,
Daniel BJ, Shin T, Curiel TJ and Zhang B: CD73 on tumor cells
impairs antitumor T-cell responses: A novel mechanism of
tumor-induced immune suppression. Cancer Res. 70:2245–2255. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Naito S, Sakamoto N, Kotoh S, Goto K,
Matsumoto T and Kumazawa J: Expression of P-glycoprotein and
multidrug resistance in renal cell carcinoma. Eur Urol. 24:156–160.
1993.PubMed/NCBI
|
|
10
|
Bak M Jr, Efferth T, Mickisch G, Mattern J
and Volm M: Detection of drug resistance and P-glycoprotein in
human renal cell carcinomas. Eur Urol. 17:72–75. 1990.PubMed/NCBI
|
|
11
|
Hofmockel G, Bassukas ID, Wittmann A and
Dӓmmrich J: Is the expression of multidrug resistance gene product
a prognostic indicator for the clinical outcome of patients with
renal cancer? Br J Urol. 80:11–17. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanamaru H, Kakehi Y, Yoshida O, Nakanishi
S, Pastan I and Gottesman MM: MDR1 RNA levels in human renal cell
carcinomas: Correlation with grade and prediction of reversal of
doxorubicin resistance by quinidine in tumor explants. J Natl
Cancer Inst. 81:844–849. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rochlitz CF, Lobeck H, Peter S, Reuter J,
Mohr B, de Kant E, Huhn D and Herrmann R: Multiple drug resistance
gene expression in human renal cell cancer is associated with the
histologic subtype. Cancer. 69:2993–2998. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Colgan SP, Eltzschig HK, Eckle T and
Thompson LF: Physiological roles for ecto-5′-nucleotidase (CD73).
Purinergic Signal. 2:351–360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shirley DG, Vekaria RM and Sévigny J:
Ectonucleotidases in the kidney. Purinergic Signal. 5:501–511.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Henttinen T, Jalkanen S and Yegutkin GG:
Adherent leukocytes prevent adenosine formation and impair
endothelial barrier function by Ecto-5′-nucleotidase/CD73-dependent
mechanism. J Biol Chem. 278:24888–24895. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eckle T, Krahn T, Grenz A, Köhler D,
Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF,
Unertl K, et al: Cardioprotection by ecto-5′-nucleotidase (CD73)
and A2B adenosine receptors. Circulation. 115:1581–1590. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu XR, He XS, Chen YF, Yuan RX, Zeng Y,
Lian L, Zou YF, Lan N, Wu XJ and Lan P: High expression of CD73 as
a poor prognostic biomarker in human colorectal cancer. J Surg
Oncol. 106:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Supernat A, Markiewicz A,
Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Sejda A, Szade
J, Czapiewski P, Biernat W and Zaczek A: CD73 expression as a
potential marker of good prognosis in breast carcinoma. Appl
Immunohistochem Mol Morphol. 20:103–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grenz A, Zhang H, Eckle T, Mittelbronn M,
Wehrmann M, Köhle C, Kloor D, Thompson LF, Osswald H and Eltzschig
HK: Protective role of ecto-5′-nucleotidase (CD73) in renal
ischemia. J Am Soc Nephrol. 18:833–845. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eble JN, Togashi K and Pisani P: Renal
cell carcinomaPathology and Genetics of Tumours of the Urinary
System and Male Genital Organs. World Health Organization
Classification of Tumors. Eble JN, Sauter G, Epstein JI and
Sesterhenn IA: IARC Press; Lyon: pp. 12–43. 2004
|
|
22
|
Stella J, Bavaresco L, Braganhol E,
Rockenbach L, Farias PF, Wink MR, Azambuja AA, Barrios CH, Morrone
FB and Oliveira Battastini AM: Differential ectonucleotidase
expression in human bladder cancer cell lines. Urol Oncol.
28:260–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mikhailov A, Sokolovskaya A, Yegutkin GG,
et al: CD73 participates in cellular multiresistance program and
protects against TRAIL-induced apoptosis. J Immunol. 181:464–475.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bavaresco L, Bernardi A, Braganhol E,
Cappellari AR, Rockenbach L, Farias PF, Wink MR, Delgado-Cañedo A
and Battastini AM: The role of ecto-5′-nucleotidase/CD73 in glioma
cell line proliferation. Mol Cell Biochem. 319:61–68. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sadej R, Spychala J and Skladanowski AC:
Ecto-5′-nucleotidase (eN, CD73) is coexpressed with metastasis
promoting antigens in human melanoma cells. Nucleosides Nucleotides
Nucleic Acids. 25:1119–1123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cho SY, Polster J, Engles JM, Hilton J,
Abraham EH and Wahl RL: In vitro evaluation of adenosine
5′-monophosphate as an imaging agent of tumor metabolism. J Nucl
Med. 47:837–845. 2006.PubMed/NCBI
|
|
27
|
Serra S, Horenstein AL, Vaisitti T, Brusa
D, Rossi D, Laurenti L, D'Arena G, Coscia M, Tripodo C, Inghirami
G, et al: CD73-generated extracellular adenosine in chronic
lymphocytic leukemia creates local conditions counteracting
drug-induced cell death. Blood. 118:6141–6152. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sadej R, Spychala J and Skladanowski AC:
Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from
various stages of human melanoma. Melanoma Res. 16:213–222. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Spychala J, Lazarowski E, Ostapkowicz A,
Ayscue LH, Jin A and Mitchell BS: Role of estrogen receptor in the
regulation of ecto-5′-nucleotidase and adenosine in breast cancer.
Clin Cancer Res. 10:708–717. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kondo T, Nakazawa T, Murata SI and Katoh
R: Expression of CD73 and its ecto-5′-nucleotidase activity are
elevated in papillary thyroid carcinomas. Histopathology.
48:612–614. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fukuda K, Sakakura C, Miyagawa K, Kuriu Y,
Kin S, Nakase Y, Hagiwara A, Mitsufuji S, Okazaki Y, Hayashizaki Y,
et al: Differential gene expression profiles of radioresistant
oesophageal cancer cell lines established by continuous
fractionated irradiation. Br J Cancer. 91:1543–1550. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hastie C, Saxton M, Akpan A, Cramer R,
Masters JR and Naaby-Hansen S: Combined affinity labelling and mass
spectrometry analysis of differential cell surface protein
expression in normal and prostate cancer cells. Oncogene.
24:5905–5913. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu J, Cui Y, Zhu J, He J, Zhou G and Yue
Z: Biological characteristics of Rh123(high) stem-like cells in a
side population of 786-O renal carcinoma cells. Oncol Lett.
5:1903–1908. 2013.PubMed/NCBI
|
|
34
|
Zhou G, Wang J, Song L, et al: Application
of renal clear cell carcinoma stem cell surface markers. China
CN201310181801.8. Filed. May 16–2013, issued January 7, 2015.
|
|
35
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rackley RR, Lewis TJ, Preston EM, Delmoro
CM, Bradley EL Jr, Resnick MI, Pretlow TP and Pretlow TG:
5′-nucleotidase activity in prostatic carcinoma and benign
prostatic hyperplasia. Cancer Res. 49:3702–3707. 1989.PubMed/NCBI
|
|
37
|
Oh HK, Sin JI, Choi J, Park SH, Lee TS and
Choi YS: Overexpression of CD73 in epithelial ovarian carcinoma is
associated with better prognosis, lower stage, better
differentiation and lower regulatory T cell infiltration. J Gynecol
Oncol. 23:274–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu XR, He XS, Chen YF, Yuan RX, Zeng Y,
Lian L, Zou YF, Lan N, Wu XJ and Lan P: High expression of CD73 as
a poor prognostic biomarker in human colorectal cancer. J Surg
Oncol. 106:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Supernat A, Markiewicz A,
Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Sejda A, Szade
J, Czapiewski P, Biernat W and Zaczek A: CD73 expression as a
potential marker of good prognosis in breast carcnoma. Appl
Immunohistochem Mol Morphol. 20:103–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Leth-Larsen R, Lund R, Hansen HV,
Laenkholm AV, Tarin D, Jensen ON and Ditzel HJ: Metastasis-related
plasma membrane proteins of human breast cancer cells identified by
comparative quantitative mass spectrometry. Mol Cell Proteomics.
8:1436–1449. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Synnestvedt K, Furuta GT, Comerford KM,
Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF and
Colgan SP: Ecto-5′-nucleotidase (CD73) regulation by
hypoxia-inducible factor-1 mediates permeability changes in
intestinal epithelia. J Clin Invest. 110:993–1002. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Spychala J, Zimmermann AG and Mitchell BS:
Tissue-specific regulation of the ecto-5′-nucleotidase promoter.
Role of the camp response element site in mediating repression by
the upstream regulatory region. J Biol Chem. 274:22705–22712. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Spychala J and Kitajewski J: Wnt and
β-catenin signaling target the expression of ecto-5′-nucleotidase
and increase extracellular adenosine generation. Exp Cell Res.
296:99–108. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang B: CD73 promotes tumor growth and
metastasis. Oncoimmunology. 1:67–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ålgars A, Karikoski M, Yegutkin GG,
Stoitzner P, Niemelӓ J, Salmi M and Jalkanen S: Different role of
CD73 in leukocyte trafficking via blood and lymph vessels. Blood.
117:4387–4393. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jalkanen S and Salmi M: VAP-1 and CD73,
endothelial cell surface enzymes in leukocyte extravasation.
Arterioscler Thromb Vasc Biol. 28:18–26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Thompson LF, Ruedi JM, Glass A, Low MG and
Lucas AH: Antibodies to 5′-nucleotidase (CD73), a
glycosyl-phosphatidylinositol-anchored protein, cause human
peripheral blood T cells to proliferate. J Immunol. 143:1815–1821.
1989.PubMed/NCBI
|
|
48
|
Allard B, Turcotte M and Stagg J:
CD73-generated adenosine: orchestrating the tumor-stroma interplay
to promote cancer growth. J Biomed Biotechnol. 2012:4851562012.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Spychala J: Tumor-promoting functions of
adenosine. Pharmacol Ther. 87:161–173. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhi X, Wang Y, Zhou X, Yu J, Jian R, Tang
S, Yin L and Zhou P: RNAi-mediated CD73 suppression induces
apoptosis and cell-cycle arrest in human breast cancer cells.
Cancer Sci. 101:2561–2569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Thiebaut F, Tsuruo T, Hamada H, Gottesman
MM, Pastan I and Willingham MC: Cellular localization of the
multidrug-resistance gene product P-glycoprotein in normal human
tissues. Proc Natl Acad Sci USA. 84:7735–7738. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cordoncardo C, O'Brien JP, Casals D and
Rittman-Grauert L: Multidrug-resistance gene (P-glycoprotein) is
expressed byendothelial cells at blood-brain barrier sites. Med
Sci. 86:695–698. 1989.
|
|
53
|
Mignogna C, Staibano S, Altieri V, De Rosa
G, Pannone G, Santoro A, Zamparese R, D'Armiento M, Rocchetti R,
Mezza E, et al: Prognostic significance of multidrug-resistance
protein (MDR-1) in renal clear cell carcinomas: A five year
follow-up analysis. BMC Cancer. 6:293–312. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fellay J, Marzolini C, Meaden ER, Back DJ,
Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G,
et al: Swiss HIV Cohort Study: Response to antiretroviral treatment
in HIV-1-infected individuals with allelic variants of the
multidrug resistance transporter 1: A pharmacogenetics study.
Lancet. 359:30–36. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hitzl M, Drescher S, van der Kuip H,
Schӓffeler E, Fischer J, Schwab M, Eichelbaum M and Fromm MF: The
C3435T mutation in the human MDR1 gene is associated with altered
efflux of the P-glycoprotein substrate rhodamine 123 from CD56+
natural killer cells. Pharmacogenetics. 11:293–298. 2001.
View Article : Google Scholar : PubMed/NCBI
|
